Celldex Therapeutics (CLDX) Gains from Investment Securities (2017 - 2018)
Celldex Therapeutics (CLDX) posted quarterly Gains from Investment Securities of $26.8 million for Q4 2018, up 22242.98% year-over-year from N/an in Q4 2017, and up 486.34% quarter-over-quarter from -$6.9 million in Q3 2018.
Powered by 
Analysis
Celldex Therapeutics (CLDX) Gains from Investment Securities (2017 - 2018) Analysis & Trends
Celldex Therapeutics' Gains from Investment Securities history runs 2 years deep, the most recent figure standing at $26.8 million for Q4 2018.
- In Q4 2018, Gains from Investment Securities rose 22242.98% year-over-year to $26.8 million; the TTM figure through Dec 2018 stood at -$1.2 million (down 266.04% YoY), while the FY2023 annual figure was -$1.1 million, down 109.89% from the prior year.
- Gains from Investment Securities for Q4 2018 stood at $26.8 million, up from -$6.9 million in the prior quarter.
- The five-year high for Gains from Investment Securities was $26.8 million in Q4 2018, with the low at -$13.6 million in Q1 2018.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Celldex Therapeutics | 3.10 Bn | 3.10 Bn | -2.57 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2018 | -1.65 Mn |
| Sep 30, 2018 | -6.94 Mn |
| Jun 30, 2018 | -7.43 Mn |
| Mar 31, 2018 | -13.60 Mn |
| Dec 31, 2017 | -600,000.00 |
| Sep 30, 2017 | -4.60 Mn |
| Jun 30, 2017 | 1.00 Mn |
| Mar 31, 2017 | 3.40 Mn |